retatrutide phase 3 results are in. TRIUMPH-1 topline: 28.3% average weight loss at 80 weeks, 30.3% at 104 weeks in participants with BMI 35 or higher. That averages 85 lbs. No pharmaceutical New Retatrutide Phase 3 Trial

However, some patients benefit from switching to alternative GLP-1 compounds or dosing protocols that produce gentler weight loss trajectories

La dosis ms baja casi nunca es la que las personas terminan tomando, dijo Korner

Hong Kong: Oxford University Press

(See the list of studies, linked here.) The EPIC trial's report concluded: "Chronic oral administration of pimobendan to dogs with echocardiographic and radiographic evidence of cardiomegaly [enlargement] secondary to MMVD, in the absence of concurrent cardiovascular medication, results in the prolongation of the preclinical period, and is safe and well tolerated." Note that, as big a step as the EPIC trial took for promoting pimobendan, its investigators still emphasized the necessity of both "echocardiographic and radiographic [x-ray] evidence" that the dog's heart is enlarged due to MVD

Average weight loss: AOD-9604 produced clinically insignificant results in its pivotal trial

By monitoring these metabolites, clinicians can gain a deeper understanding of the changes in patients' conditions and tailor treatment plans accordingly [14]